"Cambridge business big guns have given a largely warm reception to the launch of the Government's new life sciences strategy which aims to make Britain a world leader in the sector."
Genestack has been listed as one of the Key Companies to watch in the recent Frost & Sullivan report on the Growth Opportunities in the European Next-generation Sequencing Informatics Market, Forecast to 2021.
Many key scientists lack essential skills in bioinformatics and this is potentially a bottleneck for therapeutic research in big pharma. Dr Misha Kapushesky, CEO of Genestack, will discuss how increasing pressure on bioinformaticians is slowing the pace of discovery in a webinar ‘Next-generation Sequencing: New Business Models in Diagnostics and Drug Development’ organised by Frost & Sullivan on 9th August.
During the webinar, Colin Whittaker was discussing: the importance of security assurance for relying parties; different security assurance methods and the reasons for choosing ISO27001; how can relying parties assess the security evidence; how to tailor ISO27001 to smaller enterprises -the process of obtaining ISO27001 certification on the example of Genestack
For immediate release 23 May 2017 Genestack awarded ISO 27001 certification for information security management International standard recognises company's commitment to best practice Cambridge, 23 May 2017. Bioinformatics company Genestack announced today that it has obtained an international ISO 27001 certificate for best practice in information…